EichorEICHOR
Location: Grayslake Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Grayslake

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT05564390Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Phase N/A · Northwestern Medicine Grayslake Outpatient Center · PrECOG, LLC. · NCT06538038A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
Phase 1 · Acpru /Id# 279789 · AbbVie · NCT07306754Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · SWOG Cancer Research Network · NCT06769126Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Northwestern Medicine Grayslake Outpatient Center · NRG Oncology · NCT05174169Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · Alliance for Clinical Trials in Oncology · NCT06632327ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · Alliance for Clinical Trials in Oncology · NCT06876714Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT04269902E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · NRG Oncology · NCT06748222Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06649812A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
Phase 1 · Acpru /Id# 282143 · AbbVie · NCT07599761Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT05256225Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06900595Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06498635Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT07061964Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · NRG Oncology · NCT05327686De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · NRG Oncology · NCT04852887Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06058377Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT05987241Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT05564377Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · Children's Oncology Group · NCT06513962Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06317649A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT05675410Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · Northwestern Medicine Grayslake Outpatient Center · SWOG Cancer Research Network · NCT06616584Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06029270Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT07195734Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · ECOG-ACRIN Cancer Research Group · NCT06475989Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe
Phase 3 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT06422806BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · Northwestern Medicine Grayslake Outpatient Center · National Cancer Institute (NCI) · NCT05136196Optimizing Orthodontic Appliances Efficiency With Remote Dental Monitoring and Artificial Intelligence Algorithms
NA · Orthodontic Specialists of Lake County (Grayslake) · University of Illinois at Chicago · NCT05573308
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.